Jonathan E. Levitt, Esq, founding partner of boutique health care law firm Frier Levitt, LLC, discusses a recent class-action lawsuit brought against Johnson & Johnson in which an employee alleged a breach of fiduciary duty regarding her employer-sponsored pharmacy benefits.
Jonathan E. Levitt, Esq, founding partner of boutique health care law firm Frier Levitt, LLC, spoke on 2 panel discussions at the 2024 Community Oncology Conference presented by the Community Oncology Alliance (COA): “The Post-DIR Hangover: Underwater Reimbursement & Challenges” and “Legal Updates & Developments in PBM & Community Pharmacy Relationships.” Here, he discusses a recent class-action lawsuit brought against pharma giant Johnson & Johnson (J&J) in which an employee alleged a “breach of fiduciary duty” regarding her employer-sponsored pharmacy benefits.
Levitt recently coauthored an article on the J&J lawsuit that predicted the employee’s decision to bring this action will force employers to have stronger oversight of the pharmacy benefit managers (PBMs) that manage their benefits.
Transcript
Can you address how soon we might see stronger employer oversight of PBMs?
In February of this year, a woman, [Ann] Lewandowski is her name, filed a class-action lawsuit against Johnson & Johnson. Her allegation is simply that Johnson & Johnson messed up in the pharmacy benefit design. The legal term is “a breach of fiduciary duty.” Every single self-funded plan under ERISA [Employee Retirement Income Security Act of 1974] has a duty of prudence. That means that you have to intelligently look at your pharmacy benefit design.
As it relates to COA, for example, if a major employer is telling its employees, “You can't go get your oncology medication from your oncologist. You have to go to Accredo, which is owned by Express Scripts, or Caremark Specialty Pharmacy owned by CVS,” that benefit design employee at that company really has to be able to answer the question, “Why did you exclude the COA practice? Does that really make sense to you?” And so your question is, how quickly are we going to see changes? We already see changes.
At Frier Levitt, we have a plan sponsor division, and we talk to plans and coalitions of plans, and they're all asking the question, “How do we avoid breaching the duty of prudence? What do we have to do when we look at our pharmacy benefit design?” Some of the things we're saying are, “Well, are you excluding community oncology practices? Are you excluding cheap drugs, like Mark Cuban Cost Plus Drugs, when he has something for $49 that the PBM’s own specialty pharmacy is selling for $10,000?” You have to be able to answer those questions and you have to select your PBM wisely, and you have to look at your drug formulary. And you have to audit. So all these plans now know, because this Johnson & Johnson class action is the first of its kind and so plans have all taken note.
The plaintiff’s lawyers were pretty smart. What they did was they picked examples like that, where there was no rebate. This $10,000 drug was a specialty generic; there's no rebate. And so the $49—by the way, it may have been $69—$49 to $69 vs $10,500, that is a true apples-to-apples comparison. And then you have Humira examples, the net cost after rebate: $32,000 vs $8000, something like that—it’s a $20,000 difference. These are substantial differences.
Real-World Data Show Sotorasib Effective for NSCLC With KRAS Mutation
May 18th 2024Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
Read More
Health Equity and Access Weekly Roundup: May 18, 2024
May 18th 2024The US Senate hosted a panel addressing physician and health care shortages and efforts to increase minority representation in the medical field. An expert discussed initiatives to prevent senior homelessness. Advocates called for the repeal of the Comstock Act. Regulatory reforms are called for to improve rural cancer patients' access to pharmacies. Research reveals the impact of denials on patient access to immunology treatments.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More